Transmission of Quarterly Account for the Period Ended June 30, 2025

Un-Audited Financial Statements for the Quarter and Six Months Ended June 30, 2025

Corporate Information

Ehsan Ali Malik (Chairman) (Non-Executive Director)

Syed Anis Ahmed (Chief Executive Officer)

Celestino Jacinto Dos Anjos (Non-Executive Director)

Ayla Majid (Independent Director)

Muhammad Anjum Latif Rana (Non-Executive Director)*

Mohsin Ali Nathani (Independent Director) Seema Khan (Executive Director)

Muhammad Ali Shiwani

EY Ford Rhodes, Chartered Accountants

(a member firm of Ernst & Young Global Limited)

8th Floor, Faysal House,

St-02, Shahrah-e-Faisal, Karachi.

House No. 25/III/B, Jamrud Lane, University Town, Peshawar, Pakistan.

House No. 187, Aurangzeb Block,

Mr. Alejandro Granados Pozzo (Non-Executive Director) Orr, Dignam & Co.

Near Garden Town, Lahore, Pakistan.

Seema Khan (Executive Director)

Mohsin Ali Nathani (Chairman) Ayla Majid

Celestino Jacinto Dos Anjos

Mohsin Ali Nathani (Chairman) Ehsan Ali Malik

Syed Anis Ahmed

Ayla Majid (Chairperson) Syed Anis Ahmed

Seema Khan

Celestino Jacinto Dos Anjos

Syed Anis Ahmed (Chairman) Celestino Jacinto Dos Anjos Seema Khan

Mohsin Ali Nathani (Chairman) Syed Anis Ahmed

Seema Khan

Celestino Jacinto Dos Anjos

Ehsan Ali Malik (Chairman) Mohsin Ali Nathani

Syed Anis Ahmed

Syed Tabish Aseem

Muhammad Usama Jamil

Mohsin Ali Nathani (Chairman) Ayla Majid

Celestino Jacinto Dos Anjos

Mohsin Ali Nathani (Chairman) Ehsan Ali Malik

Syed Anis Ahmed

Ayla Majid (Chairperson) Syed Anis Ahmed

Seema Khan

Celestino Jacinto Dos Anjos

Syed Anis Ahmed (Chairman) Celestino Jacinto Dos Anjos Seema Khan

Mohsin Ali Nathani (Chairman) Syed Anis Ahmed

Seema Khan

Celestino Jacinto Dos Anjos

Ehsan Ali Malik (Chairman) Mohsin Ali Nathani

Syed Anis Ahmed

Syed Tabish Aseem

Muhammad Usama Jamil

Surridge & Beecheno

Standard Chartered Bank (Pakistan) Limited Deutsche Bank AG

Habib Bank Limited National Bank of Pakistan MCB Bank Limited Faysal Bank Limited Habib Metropolitan Bank Citibank

Syed Anis Ahmed

(Chief Executive Officer) Syed Tabish Aseem (Chief Financial Officer) Moien Ahmed Khan (Director Operations)

Asim Shafiq

(General Manager, Abbott Nutrition International Pakistan)

Saad Siddique

(Country Manager, Abbott Diagnostics Division Pakistan)

Dr. Shaikh Adnan Lateef

(Head of Abbott Diabetes Care Pakistan)

Asghar Huda

(Director Human Resource)

FAMCO Share Registration Services (Pvt) Limited, 8-F, Next to Hotel Faran, Nursery Block 6, P.E.C.H.S, Shahrah-e-Faisal, Karachi.

Plot No. 258 & 324, Opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, Karachi.

Plot No. 13, Sector 20,

Korangi Industrial Area, Karachi.

Plot No. 136, Street # 9, Sector 1-10/3, Industrial Area, Islamabad.

1. KM Shahpur Kanjran, Multan Road, Lahore.

   Hasanabad Gate # 2, Near Pak Arab Fertilizers, Khanewal Road, Multan..

   WEBSITE

   https://www.pk.abbott

   Directors' Report

   The Directors are pleased to present the un-audited condensed interim financial statements of your Company, for the six months ended June 30, 2025, as well as for the second quarter ended June 30, 2025.

   FINANCIAL HIGHLIGHTS

   For six months' period ended June 30, 2025

   Overall sales for the half year increased by 13% over the same period last year. Pharmaceutical sales increased by 16% driven by sustained performance of established brands. Nutritional sales increased by 20% while Diagnostics segment were down by 23% vs. same period last year mainly due to a one-off tender business impact in H1-2024 sales.

   Gross profit margin of your Company during this period improved to 35% vs 26% during the same period last year, mainly driven by price adjustments together with efficiency measures taken across the Company. Gross margin for the pharmaceutical segment improved to 34% from 26%, whereas the gross margin for Nutritional segment increased to 42% from 32%.

   Selling and distribution expenses increased by 17% against the same period last year mainly due to increased marketing and advertisement activities; part of selling and distribution expense is augmented by prior years' inflation adjustments. Net profit as a percentage of sales improved to 10% versus 7% during same period last year.

   For second quarter ended June 30, 2025

   Sales for the quarter increased by 18% over the same period last year. Pharmaceutical sales increased by 24% whereas sales for nutrition increased by 19%.

   Similar to the year-to-date results, gross profit margin of the Company improved to 36% from 24% during the same period last year.

   Operating expenses increased by 21% over the same period last year on account of higher sales promotion and forwarding expenses. Other charges increased by Rs. 373 million (285%) over the same period last year due to increase in statutory charges owing to improved profitability.

   Consequently, profit after tax for the quarter increased by Rs. 1,322 million vs. the same period last year.

   FUTURE OUTLOOK

   The pharmaceutical sector continues to operate in an evolving environment with gradual improvements in macroeconomic indicators offering cautious optimism. Recent policy steps towards pricing flexibility for nonessential medicines are encouraging however sustained reforms in the pricing framework for essential drugs remain critical to ensure uninterrupted patient access to quality treatments.

   
   
   

   Looking ahead, consistent economic stability, supportive fiscal measures and progressive regulatory alignment with global practices will be pivotal for the sector's sustenance. Your Company remains committed to mitigating potential headwinds through operational excellence, prudent cost management and strategic initiatives aimed at strengthening our market position.

   
   
   

   Syed Anis Ahmed Ehsan Ali Malik

   Chief Executive Director

   Karachi: August 27, 2025

   Abbott Pakistan

   ٹروپر ز/ٹ ی sئ اڈ

   ھتاس ھتاس ےک یہامشش ےلغ او ےنوہ متخ وک 2025 نوج 30 ےک ینپمک یک پآ ز/ٹ ی sئ اڈ

   یلام یروبع ہدش ٹڈآ �ی لی ےک ہیہام ہس یرسود یلاو ےنوہ متخ وک 20ش 2پ 5 نوج 30

   ۔�ی ےترک سوسحم یشوخ ےئوہ ےترک ɧی ےراوشوگ ں�ییsکلھ�جج یلام

   لیی ےک تدم یک ہام ھچ یلاو ےنوہ متخ وک 2025 نوج 30

   غ ت غ غ

   ہفاضا Pی 13 می �ٹ غ ج و) یعومجم یک لاس فصن می ےلباقمی غ ےک تی دمغ یسی ا یکی ٹ لی اس ہتشزگ

   یگدرکراک لسلسمی یکٹ زغ �اs مئاقکsٹ سےسئغ ہجو یک سج اوہ ہفاضاغ P 16ی مغت سغ pغغ سیش امرغاف ۔اوہ

   لاس ہتشزگ م ��مگی�غس س �sگ�اڈ ہکبج ،اوہ ہفاضا Pغ ی 20 م �و) یک�رٹsی ۔ےہ

   ش غ ٹ غ ٹ

   می 2024 ہجو ید�ی ج یک سج ،یئوہ عقاو یمک Pی 23 می ےلباقم ےک ےصرع یسا ےک ۔اھت sا اک سنsج رmی Jی ا

   ٹ ت �ق

   ےک تدم یسا یک لاس ےلھچپ

   روا ٹنمٹسجٹ �ی ا می ںغ ��می

   نجرام اک غعفانم یعومجم غ ےک ینپمک یک پآ نارغ ود ےک تدم سا

   ج ی ٹ ی ی

   رپ روط ید�ی ،گی وہ P 35 رکٹ ھsج ےس P 26 مش ئ ےلباقم

   غ ٹ غ غ غ ش ی غ غ

   34 رک ھsج ےس Pی 26 نجرام یعومجم لی ےک ہقبط pی سی امراف ۔ےھت تامادقا �وم روا وہ Pی 42 رک ھsج ےس Pی 32 نجرام یعومجم لی ےک ےقبط ےک�رٹsی ہکبج ،گی وہ Pی

   غ ی ی غ ی ت ت ت غ ۔گغی

   Pی ت 1غ7 مغ ےلباقم ےک ےصرع یسا ےک لاس ہتشزگ مغ ٹ تاجاsا ےکغ � روا �و)

   روا �و) ؛ےہٹ ہفاضا می ںٹ می رگرس یراہتشا روا گs�sی کرام ہجو ید�جی یک سجغ ،اوہ ہفی اضتت ا

   ی ی غ ی

   صلاخ ۔ےہ اھsج ےس ٹنمٹسج�ی ا یک یئاگنہم یک ںغ ولاس ہتشزگ ہصح Jی ا اک تاجاsا ےک � م ےصرع یسا لاس ہتشزگ ہکبج ےہ گی وہ P 10 رک وہ رتہب ،ےس سج انت ےک سغ ،عفانم ۔اھت Pی 7 �ی

   لیی ےک یہام ہس یرسود یلاو ےنوہ متخ وک 2025 نوج 30

   غ ت غ غ

   ۔اوہ ہفاضا Pی 1ی غ 8 می �ی غ وی) لی غ ےکش ی یہغ ام ہس می ےلباقم ےکی غ تدم ییساغ یکی لاسی ٹ ہتشی زگ

   ۔ اوہ ہفاضا P 19 م س یک �رٹsی ہکبج اوہ ہفاضا P 24 م س pسامراف

   غ غ

   ےصرع یسا ےک لاس ہتشزگ نجرام اک عفانم یعومجم اک ینپمک حرط یک جئاتن ےک Jت با ےک لاس ۔ےہ گی وہ Pی 36 رک وہ رتہب ےس Pی 24 می

   سج ،اوہ ہفاضا Pی غ 21 می ےلباقم ےک ےصرعغ یسا غ ےک لاس ہتشزگ می غ تاجاsغ ا �غ غٹ ی رپآ

   ۔ےہ ہفاضا می تاجاsا �ڈروراف روا نشومورپ سی ہجو ید�ی ج یک

   285 ش 373 غ

   ےس ہجو یک عفانم رتہب ہک وج ،اوہ ہفاضا اک (Pی غ ( ےپور لمغ ی می sغ ج راچ �ی د ۔ےہ عج� ےک ےفاضا می sج راچ ینوناق

   می ےلباقم ےک تدم یسا یک لاس ہتشزگ می عفانم دعب ےک �ی ٹ لی ےک یہام ہس ،ً�تsج�ی�ت�غ� ۔اوہ ہفاضا اک ےپور لمغ ی 1,322

   ش ہم�غغ رظنم اکٹ لبقتسم

   ں�ی ر�ا ت یش�قاعم ںاہج ،ےہ اہر رک مغ اک می لوحام ےئوہ ےتلدب لسلسم Jی ا ہبعش جpی ی سی امراف

   می ت م�ںق ��می یک ت�ی ودا یرورض �ی ت ۔ےہہ یہر رک ا�ی پ اضف یک می ای طاتحم یرتہب �ردتب می

   ں��ی لی ت ےک ت�ی ودا یرورض مہیغ � ،�ی ت ازفاہ ہلصوحت تامادقا لپ� لی اح قلعتمی ےس کچل

   غ ی

   لطعت الب J جالع یرعمی وک ں�رم ہک� �ی مہا �ی اہن تاحالصا لقتسم م مت اظن ےک ۔ےکس اج یئانب �ی یئاسر

   گنہآ مہ ےس ںولوصا یملت اعی روا ،تامادقا یلام ئنواعم ،ماکحتسا یشاعم لسلسمی غ ٹ ،لی ی ی ےک ہدنئآت

   یک پآ ۔ی ےگ ںوہ مہا �اہنت لی ےک یرا�ی پ� یکغ ش ی ےبعش سا کرو �) یلغ �غ �لیs�پ ر دنسپ یقs

   تمکح �ت ت ا روا ،ماظتنا ےک گال طغاتحم ،تغ شراہم �رپآ لی ٹ ےک ےنٹمن ےس �ج� ہنکمم ینپمکع

   ید �ج ی s لی ےک ےنانب طوبضم �ی م وک �ی زوپ یر�ہ می کی رام وج ےہ ا�ی پ لمع رپ ں�ی�لم ۔�ی ہ یئگ

   �ٹ ی �غ ی ا �غ ی پ

   /ٹ ی sئ اڈ

   
   
   
   
   
   

   ء 2025تسگا 27 :یچارک

   
   
   

   EY Ford Rhodes Chartered Accountants

   Progressive Plaza, Beaumont Road P.O..Box Karachi 75530

   Pakistan

   Tel: +9221 3565 0007-11

   Fax: +9221 3568 1965

   ey.khi@pk.ey.com ey.com/pk

   Independent Auditor's Review Report

   To the members of Abbott Laboratories (Pakistan) Limited Report on review of Interim Financial Statements Introduction

   We have reviewed the accompanying condensed interim statement of financial position of Abbott

   Laboratories (Pakistan) Limited (the Company) as at 30 June 2025 and the related condensed interim statement of profit or loss, condensed interim statement of comprehensive income, condensed interim statement of cash flows, and condensed interim statement of changes in equity and notes to the condensed interim financial statements for the six months period then ended (here-in-after referred to as the "interim financial statements"). Management is responsible for the preparation and fair presentation of these interim financial statements in accordance with accounting and reporting standards as applicable in Pakistan for interim financial reporting. Our responsibility is to express a conclusion on these interim financial statements based on our review.

   Scope of Review

   We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   Conclusion

   Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial statements are not prepared, in all material respects, in accordance with accounting and reporting standards as applicable in Pakistan for interim financial reporting.

   Other Matter

   Pursuant to the requirement of Section 237 (1) (b) of the Companies Act, 2017, only cumulative figures for the half year, presented in the second quarter accounts are subject to a limited scope review by the statutory auditors of the Company. Accordingly, the figures of the condensed interim statement of profit or loss and condensed interim statement of comprehensive income for the three months periods ended 30 June 2025 and 30 June 2024 have not been reviewed by us.

   The engagement partner on the audit resulting in this independent auditors' report is Shaikh Ahmed Salman.

   Chartered Accountants

   
   
   

   Place: Karachi

   Date: 29 August 2025

   UDIN: PR20251007625cFKorge

   Condensed Interim Statement of Financial Position

   As at June 30, 2025

   June 30,			December 31,
   2025			2024
   Note ------- Rupees in '000 ------- (Unaudited) (Audited)
   ASSETS
   NON-CURRENT ASSETS
   Property, plant and equipment	7	15,231,418		14,252,797
   Intangible assets		937		1,250
   Long-term loans and advances		124,061		114,226
   Long-term deposits		32,713		7,513
   Long-term prepayments		11,081		13,710
   Total non-current assets		15,400,210		14,389,496
   CURRENT ASSETS
   Stores and spares		535,784		529,619
   Stock-in-trade	8	13,129,576		10,694,515
   Trade debts		2,894,055		2,982,679
   Loans and advances		1,256,921		938,021
   Trade deposits and short-term prepayments		522,591		283,813
   Other receivables		1,183,723		1,182,530
   Taxation - net		90,717		468,136
   Cash and cash equivalents	9	7,174,446		6,182,349
   Total current assets		26,787,813		23,261,662
   TOTAL ASSETS		42,188,023		37,651,158
   EQUITY AND LIABILITIES
   SHARE CAPITAL AND RESERVES
   Authorised capital
   200,000,000 (December 31, 2024: 200,000,000)
   Ordinary shares of Rs.10 /- each		2,000,000		2,000,000
   Issued, subscribed and paid-up capital 97,900,302 (December 31, 2024: 97,900,302)
   Ordinary shares of Rs. 10 /- each	10	979,003		979,003
   Reserves
   - Capital		1,897,756		1,750,481
   - Revenue		23,559,321		20,995,152
   Total equity		26,436,080		23,724,636
   NON-CURRENT LIABILITIES
   Deferred taxation - net		863,987		1,052,587
   Staff retirement benefits		1,217,652		1,184,179
   Lease liabilities	11	381,654		29,545
   Total non-current liabilities		2,463,293		2,266,311
   CURRENT LIABILITIES
   Trade and other payables	12	12,276,226		10,951,662
   Unclaimed dividends		72,460		63,715
   Unpaid dividends		209,714		-
   Current maturity of lease liabilities	11	78,828		22,683
   Provisions		651,422		622,151
   Total current liabilities		13,288,650		11,660,211
   CONTINGENCIES AND COMMITMENTS	13
   TOTAL EQUITY AND LIABILITIES		42,188,023		37,651,158

   The annexed notes 1 to 21 form an integral part of these condensed interim financial statements.

   Condensed Interim Statement of Profit or Loss (Unaudited)

   For the six months and quarter ended June 30, 2025

   June 30,	June 30,		June 30,	June 30,
   2025	2024 Rupees		2025 in '000	2024

   Six Months Ended Three Months Ended

   Note

   SALES - NET

   Local		34,913,845		30,489,133		18,057,357		15,250,404
   Export		1,493,944		1,710,400		1,003,981		920,201
   		36,407,789		32,199,533		19,061,338		16,170,605
   Cost of sales		(23,792,889)		(23,879,780)		(12,288,344)		(12,301,655)
   GROSS PROFIT		12,614,900		8,319,753		6,772,994		3,868,950
   Selling and distribution expenses Administrative expenses Other charges	14
   Other income	15
   		(6,575,051)		(5,122,700)		(3,489,004)		(2,534,663)
   		6,039,849		3,197,053		3,283,990		1,334,287
   Finance costs		(37,704)		(12,599)		(33,757)		(5,938)

   (5,527,267)		(4,715,510)		(2,805,964)		(2,317,942)
   (638,195)		(556,903)		(335,172)		(288,168)
   (826,334)		(308,395)		(504,514)		(131,120)
   416,745		458,108		156,646		202,567

   (2,647,573)		(731,092)		(1,416,360)		(558,481)
   188,600		(146,340)		109,626		(82,230)

   PROFIT BEFORE MINIMUM TAX DIFFERENTIAL AND INCOME TAX

   6,002,145 3,184,454 3,250,233 1,328,349

   Minimum tax differential	-		(166,882)		-		(66,258)
   PROFIT BEFORE INCOME TAX	6,002,145		3,017,572		3,250,233		1,262,091
   INCOME TAX
   Current Deferred
   	(2,458,973)		(877,432)		(1,306,734)		(640,711)
   PROFIT FOR THE PERIOD	3,543,172		2,140,140		1,943,499		621,380
   Earnings per share - basic and diluted	36.19		21.86		19.85		6.35

   
   
   

   The annexed notes 1 to 21 form an integral part of these condensed interim financial statements.

   
   
   

   Condensed Interim Statement of Comprehensive Income (Unaudited)

   For the six months and quarter ended June 30, 2025

   Six Months Ended Three Months Ended

   June 30,

   2025

   June 30,

   2024

   June 30,

   2025

   June 30,

   2024

   Rupees in '000

   Profit for the period	3,543,172		2,140,140		1,943,499		621,380
   Other comprehensive income	-		-		-		-
   Total comprehensive income for the period	3,543,172		2,140,140		1,943,499		621,380

   The annexed notes 1 to 21 form an integral part of these condensed interim financial statements.

   Condensed Interim Statement of Cash Flows (Unaudited)

   	Note	June 30, 2025 - Rupees in	June 30, 2024 '000 -------
   CASH FLOWS FROM OPERATING ACTIVITIES
   Cash generated from operations	16	5,442,215	1,981,122
   Income tax paid		(2,270,154)	(1,297,698)
   Minimum tax differential paid		-	(166,882)
   Long-term loans and advances - net		(9,835)	(9,371)
   Long-term deposits - net		(25,200)	-
   Long-term prepayments - net		2,629	(5,754)
   Contributions to staff retirement benefit funds		(166,366)	(143,120)
   Net movement in provisions		29,271	-
   Net cash generated from operating activities		3,002,560	358,297
   CASH FLOWS FROM INVESTING ACTIVITIES
   Additions to property, plant and equipment		(1,558,597)	(1,040,181)

   For the six months ended June 30, 2025

   150,585

   53,602

   Sale proceeds from disposal of operating fixed assets

   Interest income	201,732		239,125
   Net cash used in investing activities	(1,206,280)		(747,454)
   CASH FLOWS FROM FINANCING ACTIVITIES
   Bank charges paid	(5,073)		(4,883)
   Interest portion of lease liabilities paid	(18,105)		(12,391)
   Principal portion of lease liabilities paid	(20,461)		(77,532)
   Dividends paid	(760,544)		(1,030,333)
   Net cash used in financing activities	(804,183)		(1,125,139)
   NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS	992,097		(1,514,296)

   6,182,349		5,036,712
   7,174,446		3,522,416

   CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD

   CASH AND CASH EQUIVALENTS AT END OF THE PERIOD

   
   
   

   The annexed notes 1 to 21 form an integral part of these condensed interim financial statements.

   
   
   

   Condensed Interim Statement of Changes in Equity (Unaudited)

   For the six months ended June 30, 2025

   Share Capital

Rupees in '000

payments'

@ Rs. 10/- per share

E

The annexed notes 1 to 21 form an integral part of these condensed interim financial statements.

1. THE COMPANY AND ITS OPERATIONS

   Abbott Laboratories (Pakistan) Limited (the Company) is a public limited company incorporated in Pakistan on July 02, 1948, and its shares are quoted on Pakistan Stock Exchange. The address of its registered office is Plot No. 258 & 324, opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, Karachi. The Company is principally engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital and consumer products.

2. STATEMENT OF COMPLIANCE

   "These condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting which comprise of International Accounting Standard (IAS) 34 - 'Interim Financial Reporting', issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017 (the Act) and provisions of and directives issued under the Act. Where the provisions of and directives issued under the Act differ with the requirements of IAS 34, the provisions of and directives issued under the Act have been followed. "

3. BASIS OF PREPARATION

   These condensed interim financial statements are un-audited but subject to limited scope review by the statutory auditors as required under Section 237 of the Act. These condensed interim financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the annual financial statements of the Company for the year ended December 31, 2024.

   The figures of the condensed interim statement of profit or loss, condensed interim statement of comprehensive income for the three months ended June 30, 2025 and June 30, 2024 and notes forming part thereof have not been reviewed by the statutory auditors of the Company, as they are required to review only the cumulative figures for the six months ended June 30, 2025.

   These condensed interim financial statements are presented in Pakistan Rupees, which is the Company's functional and presentation currency.

4. MATERIAL ACCOUNTING POLICY INFORMATION

   The accounting policies and methods of computation adopted in the preparation of these condensed interim financial statements are consistent with those followed in the preparation of the Company's annual financial statements for the year ended December 31, 2024.

   The Company follows the practice of conducting actuarial valuation annually at the year end. Hence, the impact of re-measurement of post-employment benefit plans has not been incorporated in these condensed interim financial statements.

5. NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS TO INTERNATIONAL FINANCIAL REPORTING STANDARDS

   There are certain amendments to existing accounting and reporting standards that have become applicable to the Company for accounting periods beginning on or after January 01, 2025. These are either considered to be not relevant or do not have any significant impact and accordingly, have not been detailed in these condensed interim financial statements.

6. SIGNIFICANT ACCOUNTING JUDGEMENTS, ESTIMATES AND FINANCIAL RISK MANAGEMENT

   The preparation of the financial statements in conformity with the approved accounting standards, as applicable in Pakistan, requires management to make judgements and

   estimates that affect the application of policies and the reported amount of assets, liabilities, income, expenses and accompanying disclosures.

   The judgements and estimates are based on historical experience and various other factors that are believed to be reasonable under the circumstances and are reviewed on an ongoing basis. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods. Revisions to accounting estimates are accounted for prospectively.

   Judgements and estimates made by the management in the preparation of these condensed interim financial statements are the same as those applied in the Company's annual financial statements for the year ended December 31, 2024.

   The Company's financial risk management objectives and policies are consistent with those disclosed in the annual financial statements as at and for the year ended December 31, 2024.

   June 30, December 31,

   2025 2024

   Note ---- Rupees in '000 ----

   (Un-audited) (Audited)

7. PROPERTY, PLANT AND EQUIPMENT

   Operating fixed assets 10,748,327 11,329,199

   Capital work-in-progress 7.2 4,073,256 2,858,741 Right-of-use assets 409,835 64,857

   15,231,418 14,252,797

   1. Operating fixed assets

      1. Additions to operating fixed assets during the period were as follows:

         Six months ended June 30, June 30,

         2025 2024

         ---- Rupees in '000 ----

         (Unaudited) (Audited)

         Plant and machinery	6,844	1,825,111
         Vehicles	187,546	163,531
         Computers	94,567	-
         Service equipment	55,125	102,493
         	344,082	2,091,135

      2. Following were the disposals made during the period:

         Accumulated Net book Cost depreciation value

         Note ---- Rupees in '000 ----

         June 30, 2025 (Unaudited) Plant and machinery		6,059	4,949	1,110
         Vehicles	7.1.2.1	68,242	41,056	27,186
         Office Equipment		287	272	15
         Service equipment		64,775	38,865	25,910
         		139,363	85,142	54,221
         June 30, 2024 (Unaudited) Plant and machinery		22,643	20,558	2,085
         Vehicles	7.1.2.1	96,192	67,151	29,041
         		118,835	87,709	31,126

         1. Includes disposal of vehicles to the key management personnel costing Rs. 14.041 million (June 30, 2024: Rs. 48.057 million) having net book value of Rs. 4.705 million (June 30, 2024: Rs.13.427 million) made in accordance with the Company's policy.

      3. Depreciation charge for the period amounted to Rs. 870.733 million (June 30, 2024: Rs. 827.155 million).

         June 30, December 31,

         2025 2024

         ---- Rupees in '000 ----

         7.2	Capital work-in-progress	(Un-audited)	(Audited)
         	Plant and machinery and buildings	3,877,672	2,635,765
         	Vehicles	142,232	128,409
         	Office equipment and computers	53,352	94,567
         		4,073,256	2,858,741

         1. Additions to capital work-in-progress during the period amounted to Rs. 1,503.472 million (June 30, 2024: Rs. 937.688 million) and transfers from capital work-in-progress during the period amounted to Rs. 288.957 million (June 30, 2024: Rs. 1,988.642 million)

         1. Right-of-use assets

            1. Additions to right-of-use assets during the period amounted to Rs. 414.189 million (June 30, 2024: Nil) in respect of a new leased location for the Company's city office.

            2. Depreciation charge on right-of-use assets for the period amounted to Rs. 69.211 million (June 30, 2024: Rs. 45.302 million).

         June 30, December 31,

         2025 2024

         Note ---- Rupees in '000 ----

         (Un-audited) (Audited)

8. STOCK-IN-TRADE

   Raw and packing materials In hand	8.1	5,679,932	4,713,839
   Less: provision for obsolete and slow-moving items	8.2	203,793	195,461
   		5,476,139		4,518,378
   In transit		1,350,006		1,312,217
   		6,826,145		5,830,595
   Work-in-process	8.3	686,961		611,605
   Finished goods
   In hand Less: provision for obsolete and slow-moving items	8.4 8.5	4,653,368 256,770		4,013,026 187,039
   		4,396,598	3,825,987
   In transit		1,219,872	426,328
   		5,616,470	4,252,315
   		13,129,576	10,694,515

   1. Includes items costing Rs. 407.435 million (December 31, 2024: Rs. 665.353 million) valued at net realisable value of Rs. 339.538 million (December 31, 2024: Rs. 589.105 million) resulting in a write down of Rs. 67.897 million (December 31, 2024: Rs. 76.248 million).

   2. Movement of provision for obsolete and slow-moving raw and packing materials is as follows:

      June 30, December 31,

      2025 2024

      ---- Rupees in '000 ----

      (Un-audited) (Audited)

      Balance at the beginning of the period/year 195,461 333,306

      Charge for the period/year 55,151 184,322 Write offs during the period/year (46,819) (322,167)

      Balance at the end of the period/year 203,793 195,461

      `

   3. Includes items costing Rs. 51.398 million (December 31, 2024: Rs. 4.115 million) valued at net realisable value of Rs. 33.555 million (December 31, 2024: Rs. 3.894 million) resulting in a write down of Rs. 17.843 million (December 31, 2024: Rs. 0.221 million).

   4. Includes items costing Rs. 182.698 million (December 31, 2024: Rs. 206.178 million) valued at net realisable value of Rs. 107.792 million (December 31, 2024: Rs. 146.762 million) resulting in a write down of Rs. 74.906 million (December 31, 2024: Rs. 59.416 million).

   5. Movement of provision for obsolete and slow-moving finished goods is as follows:

      June 30, December 31,

      2025 2024

      Note ---- Rupees in '000 ----

      (Un-audited) (Audited)

      Balance at the beginning of the period/year 187,039 199,573

      Charge for the period/year 228,935 176,710 Write offs during the period/year (159,204) (189,244)

      Balance at the end of the period/year 256,770 187,039

9. CASH AND CASH EQUIVALENTS

   With banks

   Saving accounts:

   - local currency 9.1 5,135,129 4,610,252

   Current accounts:

   • local currency

   • foreign currency

     In hand

   • local currency

   • foreign currency

   403,714

   1,630,036

2,033,750 1,566,071

5,567 6,026

7,174,446 6,182,349

1. 1. These saving accounts carry mark-up rate of 5% to 10.50% (December 31, 2024: 6.50% to 13.50%) per annum.

   2. Cash and cash equivalents include the following balances with related parties:

      Saving	Current	Saving	Current
      Accounts	Accounts	Accounts	Accounts

      June 30, December 31,

      2025 2024

      Rupees '000

      Un-audited Audited

      Standard Chartered

      Bank (Pakistan) Limited	1,990,266	839,293	4,033,657	823,420
      Habib Metropolitan
      Bank Limited	523,029	413,062	504,636	22,573

      2,513,295 1,252,355 4,538,293 845,993

2. ISSUED, SUBSCRIBED AND PAID-UP CAPITAL

   As at June 30, 2025, Abbott Asia Investments Limited (the Holding Company) held 76,259,454 (December 31, 2024: 76,259,454) shares with the total shareholding

   of 77.90% (December 31, 2024: 77.90%). The ultimate holding company is Abbott Laboratories, USA.

3. LEASE LIABILITIES

   The Company has lease contracts for warehouses, sales offices and city office used in its operations. These leases generally have lease terms between 3 to 5 years. In general, the Company is restricted from assigning and subleasing the leased assets. These lease contracts include extension and termination options subject to the mutual consent of the Company and the lessors. The Company is bound by certain covenants which include, but are not limited to payment of certain taxes and to exercise reasonable care.

   Following is the maturity analysis of discounted lease liabilities recognised by the Company:

   June 30, December 31,

   2025 2024

   Note ---- Rupees in '000 ----

   (Un-audited) (Audited)

   Not later than one year 78,828 22,683 Later than one year but not later than five years 381,654 29,545

   1. 460,482 52,228

      11.1 Movement of lease liabilities is as follows:

      Balance at the beginning of the period/year 52,228 158,218

      Additions 414,189 -

      Accretion of interest 32,631 11,739

      Payments (38,566) (117,729)

      Balance at the end of the period/year 460,482 52,228

4. TRADE AND OTHER PAYABLES

   Creditors 1,005,937 1,684,234

   Accrued liabilities 5,987,157 5,344,592

   Bills payable 3,777,519 2,704,992

   Contract liabilities 229,797 394,392

   Payable to related parties 403,817 369,595

   Central Research Fund 60,629 92,145

   Workers' Welfare Fund 312,495 173,951

   Workers' Profit Participation Fund 323,194 24,205

   Refund liabilities 145,090 140,351

   Others 30,591 23,205

   12,276,226 10,951,662

5. CONTINGENCIES AND COMMITMENTS

   1. Contingencies

      There is no material change in the status of contingencies from what is disclosed in note 10.1 to the annual audited financial statements for the year ended December 31, 2024.

   2. Commitments

      1. Commitments for capital expenditure as at June 30, 2025, aggregated to Rs. 991.782 million (December 31, 2024: Rs. 802.658 million).

      2. Commitments in respect of letters of credit as at June 30, 2025, aggregated to Rs. 1,787.343 million (December 31, 2024: Rs. 1,603.211 million). This includes commitments in respect of letters of credit outstanding from Standard Chartered Bank (Pakistan) Limited (related party) amounting to Nil (December 31, 2024: 34.542 million) and from Habib Metropolitan Bank Limited (related party) amounting to Rs. 397.231 million (December 31, 2024: 1,060.163 million).

      3. The Company has given bank guarantees as at June 30, 2025, of Rs. 866.793 million (December 31, 2024: 827.108 million) to the Customs Department, a utility company and other institutions against tenders. This includes bank guarantees issued through Standard Chartered Bank (Pakistan) Limited (related party) amounting to Rs. 207.338 million (December 31, 2024: 380.256 million).

      4. The Company has obtained short-term financing facilities from various commercial banks amounting to Rs. 7,600 million (December 31, 2024: Rs. 6,600 million). These facilities can be utilised for letters of credit, bank guarantees and running finance / short-term loans. These include short-term financing facilities obtained from Standard Chartered Bank (Pakistan) Limited (related party) amounting to Rs. 2,900 million (December 31, 2024: 2,900 million) and from Habib Metropolitan Bank Limited (related party) amounting to Rs. 1,500 million (December 31, 2024: 1,500 million).

         However, the running finance / short-term loan utilisation cannot exceed Rs. 3,290 million (December 31, 2024: Rs. 3,290 million). The running finance / short-term loan carries mark-up at rates ranging from KIBOR minus 0.25% to flat KIBOR (December 31, 2024: KIBOR minus 0.25% to flat KIBOR) per annum and are secured against first joint pari passu hypothecation charge over stocks and book debts of the Company, ranking hypothecation charge over stocks and book debts of the Company, promissory notes, and counter guarantees. Neither has the Company utilised any amount against running finance / short-term loan facilities, nor has pledged its inventory at the statement of financial position date.

6. OTHER CHARGES

Six months ended June 30, 2025

Six months ended June 30, 2024

---- Rupees in '000 ----

Six months ended June 30, 2025

Six months ended June 30,

2024

---- Rupees in '000 ----

Decrease / (increase) in current assets

Stores and spares (6,165) 17,927

Stock-in-trade (2,719,147) 1,036,899

Trade debts (70,269) (593,540)

Loans and advances (318,900) (632,104)

Trade deposits and short-term prepayments (238,778) 16,668

Other receivables 9,347 208,491

(3,343,912) 54,341

Increase / (decrease) in current liabilities

Trade and other payables 1,324,564 (2,263,149)

(2,019,348) (2,208,808)

1. TRANSACTIONS WITH RELATED PARTIES

   The related parties of the Company comprise of the Holding Company, Ultimate Holding Company, group companies, companies under common directorship, staff retirement benefit plans, directors and key management personnel. All the transactions with related parties are entered into at agreed terms in the normal course of business as approved by the Board of Directors of the Company. Transactions with related parties during the period are as follows:

   Six months ended June 30, 2025

   Six months ended June 30, 2024

   ---- Rupees in '000 ----

   Holding Company	(Un-audited)	(Un-audited)
   Dividend paid	476,622	1,029,503
   Group companies Sale of goods	590,402	657,096
   Purchase of materials	12,829,821	7,688,261
   Technical service fee	178,442	150,530
   Reimbursement of expenses from related parties	323,292	221,450
   Reimbursement of expenses to related parties	23,509	3,960
   Other income	74,457	80,727
   Staff retirement benefit funds Contribution to Pension Fund	132,657	119,897
   Contribution to Provident Fund	88,073	76,412
   Contribution to Gratuity Fund	34,954	24,714
   Key management personnel Short-term employee benefits	392,209	391,107
   Post-employment benefits	32,248	28,912
   Directors Fee for attending meetings	2,100	2,100

2. SEGMENT ANALYSIS

   1. Segment wise operating results for six months ended (Un-audited):

      June 30, 2025
      Pharmaceutical	Nutritional	Diagnostic	Others	Total

      June 30, 2024
      Pharmaceutical	Nutritional	Diagnostic	Others	Total

      Rupees in '000

      Sales
      Local	25,584,692	10,076,942	3,049,214	1,151,329	39,862,177		21,501,220	8,343,269	3,232,689	1,011,861	34,089,039
      Export	1,493,944	-	-	-	1,493,944		1,710,400	-	-	-	1,710,400
      Less:
      Sales return	31,981	32,287	183,126	8,145	255,539		43,724	18,089	-	2,595	64,408
      Trade discounts	1,781,409	549,218	-	37,739	2,368,366		1,490,915	446,221	-	28,158	1,965,294
      Sales tax and excise duty	239,584	1,583,000	389,000	112,843	2,324,427		188,949	1,307,641	19,868	53,746	1,570,204
      Sales - net	25,025,662	7,912,437	2,477,088	992,602	36,407,789		21,488,032	6,571,318	3,212,821	927,362	32,199,533
      Cost of sales	(16,485,410)	(4,561,630)	(2,097,919)	(647,930)	(23,792,889)		(15,895,194)	(4,461,743)	(2,784,773)	(738,070)	(23,879,780)
      Gross profit	8,540,252	3,350,807	379,169	344,672	12,614,900		5,592,838	2,109,575	428,048	189,292	8,319,753
      Selling and distribution expenses	(3,620,183)	(1,434,075)	(301,731)	(171,278)	(5,527,267)		(3,139,970)	(1,165,041)	(217,976)	(192,523)	(4,715,510)
      Administrative expenses	(535,746)	(79,715)	(22,734)	-	(638,195)		(459,776)	(78,405)	(18,722)	-	(556,903)
      Segment result	4,384,323	1,837,017	54,704	173,394	6,449,438		1,993,092	866,129	191,350	(3,231)	3,047,340

   2. Segment wise operating results for the second quarter (Un-audited):

      June 30, 2025
      Pharmaceutical	Nutritional	Diagnostic	Others	Total

      June 30, 2024
      Pharmaceutical	Nutritional	Diagnostic	Others	Total

      Rupees in '000

      13,423,546	5,060,739	1,637,585	566,966	20,688,836		10,740,931	4,251,081	1,547,634	567,189	17,106,835
      1,003,981	-	-	-	1,003,981		920,201	-	-	-	920,201
      15,115	15,194	183,126	3,881	217,316		30,798	9,573	-	1,563	41,934
      929,227	284,115	-	20,531	1,233,873		761,625	230,538	-	16,642	1,008,805
      124,994	796,269	203,497	55,530	1,180,290		94,513	667,522	10,956	32,701	805,692
      13,358,191	3,965,161	1,250,962	487,024	19,061,338		10,774,196	3,343,448	1,536,678	516,283	16,170,605
      (8,636,605)	(2,269,409)	(1,090,494)	(291,836)	(12,288,344)		(8,130,639)	(2,319,518)	(1,419,336)	(432,162)	(12,301,655)
      4,721,586	1,695,752	160,468	195,188	6,772,994		2,643,557	1,023,930	117,342	84,121	3,868,950
      (1,879,475)	(693,788)	(121,481)	(111,220)	(2,805,964)		(1,596,720)	(511,606)	(108,333)	(101,283)	(2,317,942)
      (285,430)	(41,205)	(8,537)	-	(335,172)		(242,934)	(34,656)	(10,578)	-	(288,168)
      2,556,681	960,759	30,450	83,968	3,631,858		803,903	477,668	(1,569)	(17,162)	1,262,840

      Sales Local Export Less:

      Sales return Trade discounts

      Sales tax and excise duty

      Sales - net Cost of sales

      Gross profit

      Selling and distribution expenses

      Administrative expenses Segment result

   3. Reconciliation of segment results with profit before taxation (Un-audited)

Six Months Ended Quarter Ended

June 30,

2025

June 30,

2024

June 30,

2025

June 30,

2024

Rupees in '000